Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alizyme licenses Colal-Pred to Norgine

This article was originally published in Scrip

Executive Summary

Alizyme Therapeuticshas granted Norginethe exclusive rights to Colal-Pred (prednisolone sodium metasulfobenzoate), for the treatment of ulcerative colitis, in Europe, South Africa, Australia and New Zealand. Norgine will now develop and market Colal-Pred in the areas and will pay Alizyme €2 million up-front, with the possibility of milestone payments of up to €41 million. Norgine will cover all commercialisation costs and will pay double-digit royalty sales to Alizyme.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts